ill take a buyout with chance of $15bil in sales a year
With more than two million people affected by ischemic stroke each year in the States, Europe and Japan, the company estimates that an effective and safe therapy for that indication alone could generate more than $15 billion in sales annually. If Athersys were to successfully develop a safe and effective, “off the shelf” therapy for stroke, it would quickly become an industry leader. The company has five clinical programs and a broad range of preclinical programs in the inflammatory, neurological and cardiovascular areas and a partnership with Pfizer that should produce clinical data later this year. Despite this breadth, a solid balance sheet, and some significant institutional shareholders, the company has a paltry $65 million market cap, which is likely why investors have recently begun to pay attention.
I agree.. we should see a continued run up from here. Yesterday, the volume was lower than the last few trading days and it is my opinion it was profit taking...today might be interesting..I suspect we finish up a little with more than average volume. JMHO